Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC

AI Insight

This study evaluated the combination of sacituzumab tirumotecan (an antibody-drug conjugate targeting TROP2) with pembrolizumab (an anti-PD-1 immunotherapy) in patients with PD-L1-negative advanced non-small cell lung cancer (NSCLC). The trial assessed whether this combination therapy could provide clinical benefit in a patient population that typically responds poorly to immunotherapy alone. Results regarding efficacy and safety outcomes in this specific subgroup of NSCLC patients were examined.

Why it matters

PD-L1-negative NSCLC patients have limited treatment options since they generally do not benefit from standard immunotherapy. This combination approach could potentially expand therapeutic options for approximately 30-40% of advanced NSCLC patients who lack PD-L1 expression, addressing a significant unmet clinical need.